Myricx Bio
Generated by Meeveem AI
"Developing first-in-class ADCs based on novel NMT inhibition to treat cancer"
London
•11 - 50 Employees
•Biotechnology
About Myricx Bio
Myricx Bio is a UK biotech company advancing a completely novel approach to cancer therapy through antibody drug conjugates. The company has developed a proprietary platform based on inhibitors of N-myristoyltransferases, an enzyme critical to cancer cell survival, creating a new class of selective cytotoxic payloads that addresses a significant gap in current ADC development. The company is progressing a pipeline of differentiated ADCs targeting validated cancer antigens including B7-H3 and HER2 for solid tumours. With compelling preclinical data demonstrating efficacy and safety across multiple cancer types, Myricx is preparing to enter clinical trials in 2026, backed by leading life science investors and a team with proven ADC development expertise.
15
Team Members
2019
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where cancer patients benefit from highly effective, well tolerated therapies enabled by a novel class of antibody drug conjugates
Our Mission
At Myricx Bio, our mission is to discover and develop first-in-class antibody drug conjugates based on NMT inhibition to address serious unmet needs in oncology